There are several biologic drugs approved for use in Canada comprising an estimated 14-16 per cent of the prescription pharmaceutical market.
Canada amended its Data Protection Regulations in 2006 to provide protection for innovative drugs in a second attempt to implement.
Canada’s 1994 NAFTA
By a decision of Justice Zinn dated April 30, 2013, the Federal Court quashed a Board’s decision on excessive pricing of Copaxone.
In an industry where one out of 10,000 drugs makes it to market, and where many drugs fail after millions of dollars of investment, one of the challenges is to create an environment that enhances the chance of success and mitigates the high cost of failures.
The most thought-provoking book I read during my winter vacation this year was Salt Sugar Fat: How the Food Giants Hooked Us by Michael Moss.
On April 26, 2013, Health Canada published a notice to inform clinical trial sponsors that information about Clinical Trial Applications ("CTAs") will be published.
In the recent decision, the British Columbia Court of Appeal addressed the issue of liability on the part of a Canadian government regulator for damages arising out of negligent performance of its duties where the performance of those duties led to a recall of the plaintiff's product.
A number of discussion relating to manufacturing, sales and distribution law.
In fall 2011, Health Canada began charting a course for the transition of food-like Natural Health Products to the food regulatory framework.
The recent decision of the Federal Court of Appeal in Minister of Health v. Celgene Inc. marks the second split decision of that court in as many months on the data protection provision of the Food and Drug Regulations.
In an era of heightened awareness regarding health and obesity, consumers are taking a much greater interest in the foods they eat.
AstraZeneca Canada Inc. and AstraZeneca AB ("AstraZeneca") brought an application pursuant to section 6 of the Patented Medicines (Notice of Compliance) Regulations for an order prohibiting the Minister of Health from issuing a Notice of Compliance to Ranbaxy Pharmaceuticals Canada Inc.
On February 25, 2013, Progressive Conservative MPP, Peter Shurman (Thornhill), introduced Bill 5 (Comprehensive Public Sector Compensation Freeze Act, 2013).
The provinces of Ontario, Alberta, Prince Edward Island, New Brunswick and Manitoba have each enacted franchise legislation which requires pre-sale disclosure to prospective franchisees in order to ensure that a prospective franchisee has the information necessary to make an informed investment decision.
As of January 1, 2013, producers of pharmaceuticals, including natural heath products, are now required to provide for the collection and disposal of expired or unused pharmaceutical products in Ontario.
For a little more than a year, Ontario hospitals have been subject to the Freedom of Information and Protection of Privacy Act ("FIPPA"). Freedom of information ("FOI") has introduced significant change to many hospitals.
Health Canada has released a new guidance document and checklist for food additive submissions, concurrent with the transition to the food additive lists in place of the tables set out in the Food and Drug Regulations.
Over the last few months, the Canadian Food Inspection Agency and the Food Directorate at Health Canada have taken a fundamental shift in their approach to permitted claims for food products.
After a decade-long battle, Health Canada has announced its intention to get out of the business of supplying medicinal marijuana to Canadians.
The "Natural Health Products Regulations" was repealed as of February 2013 as planned.